Item 5.07 Submission of Matters to a Vote of Security Holders.

On March 16, 2022, Clinigence Holdings, Inc. (the "Company") held a special meeting of stockholders in lieu of its annual meeting (the "Special Meeting") to consider eight proposals related to the Company's contemplated merger (the "Merger") with Nutex Health Holdco LLC ("Nutex") pursuant to the Agreement and Plan of Merger dated as of November 23, 2021 (the "Merger Agreement") among the Company, Nutex, Nutex Acquisition LLC, Micro Hospital Holding LLC, Nutex Health LLC, and Tom Vo, as the Nutex Representative. Each of the Company's proposals was approved by the requisite vote of the Company's stockholders as described below.

At the close of business on January 27, 2022, the record date for the Special Meeting, there were 47,200,627 shares of common stock of the Company outstanding. The holders of a total of 36,424,794 shares of the Company's common stock were represented at the Special Meeting in person or by proxy, representing approximately 77% of the Company's shares of common stock entitled to vote at the Special Meeting, which total constituted a quorum for the Special Meeting in accordance with the Company's bylaws.

The proposal to approve the Merger and the other transactions contemplated by the Merger Agreement , including the issuance of shares of common stock of the Company to Nutex members as consideration in the Merger (Proposal No. 1), the proposal to approve the Amended and Restated Certificate of Incorporation of the Company (the "Charter") to change the Company's name, to increase the number of authorized shares of Common Stock of the Company and to remove authorized shares of preferred stock (Proposal No.2), the proposal to approve the Amended and Restated Bylaws ("Bylaws") of the Company to change the Company's name, change the voting threshold required to amend the Bylaws, and provide that the Court of Chancery in Delaware or state or federal courts located within Delaware be the exclusive forum over certain actions and claims (Proposal No. 3), the proposal to approve the Amended and Restated Nutex 2022 Equity Incentive Plan (Proposal No. 4), the proposal to elect seven directors to the Company's board of directors (Proposal No. 5), the proposal to approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers pursuant to the golden parachute proposal (the "Golden Parachute Proposal") (Proposal No. 6), the proposal to approve the auditor ratification (the "Auditor Ratification Proposal") (Proposal No. 7) and the proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary (Proposal No. 8) each exceeded the requisite percentages for approval of such proposal. The stockholder approvals are subject to the completion of the Merger.

The final voting results for each of these proposals is set forth below. Brokers did not have discretionary authority to vote for any of the proposals for the shares of the Company's common stock held in street name, and as a result, no broker non-votes were received for any proposals. For more information on these proposals, please refer to the Company's joint proxy statement/prospectus for the Special Meeting, filed with the Securities and Exchange Commission on February 14, 2022.



  2

Proposal 1. To approve the Merger pursuant to the terms and conditions of the Merger Agreement and the transactions contemplated thereunder:

36,390,577 For 34,211 Against 6 Abstain 0 Broker Non-Votes

Proposal 2. Approve the Charter [to change the Company's name and increase the number of shares of Common Stock the Company is authorized to issue and remove authorized shares of preferred stock:

36,390,583 For 34,211 Against 0 Abstain 0 Broker Non-Votes

Proposal 3. Approve the Bylaws to change the Company's name, change the voting threshold to amend the Bylaws, and provide that Delaware courts be the exclusive form for certain actions and claims:

36,216,112 For 208,682 Against 0 Abstain 0 Broker Non-Votes

Proposal 4. Approve the Amended and Restated Nutex 2022 Equity Incentive Plan:

36,284,370 For 136,289 Against 4,135 Abstain 0 Broker Non-Votes

Proposal 5. To elect seven directors to serve as members of the Company's board:



Name                           For     Withheld  Broker Non-Votes
Warren Hosseinion, M.D.     36,387,570  37,224          0
Thomas T. Vo, M.D.          35,852,302  572,492         0
Matthew S. Young, M.D.      35,678,004  746,790         0
John Waters                 34,852,302 1,572,492        0

Cheryl Grenas, R.N., M.S.N. 35,852,302 572,492 0 Michael L. Reed

             34,795,159 1,629,635        0
Mitchell Creem              34,852,302 1,572,492        0

Proposal 6. To consider and vote on a proposal to approve, in a non-binding advisory vote, certain compensation arrangements for the Company's named executive officers pursuant to the Golden Parachute Proposal:

33,424,114 For 1,312,725 Against 1,687,955 Abstain 0 Broker Non-Votes

Proposal 7. Approve the Auditor Ratification Proposal:

35,852,302 For 34,210 Against 538,282 Abstain 0 Broker Non-Votes

Proposal 8. To adjourn the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5, 6, or 7:

35,603,503 For 208,498 Against 612,793 Abstain 0 Broker Non-Votes

Item 7.01. Regulation FD Disclosure.

On March 16, 2022, the Company issued a press release announcing the results of the Special Meeting. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information furnished pursuant to this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section and is not to be incorporated by reference into any filings of the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No. Description
99.1          Press Release dated March 16, 2022

3

© Edgar Online, source Glimpses